Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Breaks Below Two Hundred Day Moving Average - Time to Sell?

Key Points

• Oramed Pharmaceuticals shares fell below their 200-day moving average, trading as low as $4.06 versus the $4.27 average, and last changing hands at $4.14.
• Analyst sentiment remains cautious: the stock carries an overall “Hold” rating, despite one upgrade to “Buy.” The company also missed quarterly earnings expectations, reporting a $0.09 loss per share versus the expected $0.43 profit.
• Insiders sold shares under pre-arranged trading plans, including the COO’s 30,000-share sale and CFO’s 20,000-share sale at $4.51 per share. Insiders retain 20.77% ownership, while institutional investors own 12.73%.

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Get Free Report) shares crossed below its two hundred day moving average during trading on Wednesday. The stock has a two hundred day moving average of $4.27 and traded as low as $4.06. Oramed Pharmaceuticals shares last traded at $4.14, with a volume of 84,313 shares changing hands.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on ORMP shares. Wall Street Zen upgraded shares of Oramed Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday, August 15th. Weiss Ratings reissued a "hold (c+)" rating on shares of Oramed Pharmaceuticals in a research note on Tuesday, September 8th. One research analyst has rated the stock with a Hold rating. According to data from MarketBeat, the company has an average rating of "Hold".

Oramed Pharmaceuticals Stock Performance

The company has a 50 day simple moving average of $4.65 and a 200 day simple moving average of $4.27. The company has a market capitalization of $172.22 million, a PE ratio of 1.00 and a beta of 1.29.

Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) last announced its earnings results on Monday, August 10th. The biotechnology company reported ($0.09) EPS for the quarter, missing analysts' consensus estimates of $0.43 by ($0.52). As a group, equities research analysts anticipate that Oramed Pharmaceuticals Inc. will post 1.47 EPS for the current year.

Insider Activity at Oramed Pharmaceuticals

In other Oramed Pharmaceuticals news, COO Joshua Hexter sold 30,000 shares of the firm's stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $4.51, for a total value of $135,300.00. Following the transaction, the chief operating officer owned 1,328,130 shares in the company, valued at approximately $5,989,866.30. This trade represents a 2.21% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Avraham Gabay sold 20,000 shares of Oramed Pharmaceuticals stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $4.51, for a total transaction of $90,200.00. Following the sale, the chief financial officer directly owned 861,076 shares in the company, valued at approximately $3,883,452.76. This trade represents a 2.27% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 20.77% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Oramed Pharmaceuticals

Large investors have recently modified their holdings of the business. Ritholtz Wealth Management purchased a new position in shares of Oramed Pharmaceuticals in the first quarter worth about $529,000. Hillsdale Investment Management Inc. acquired a new position in Oramed Pharmaceuticals during the first quarter worth about $331,000. Bank of New York Mellon Corp acquired a new position in Oramed Pharmaceuticals during the second quarter worth about $381,000. OMERS ADMINISTRATION Corp purchased a new stake in Oramed Pharmaceuticals during the 1st quarter valued at about $63,000. Finally, Kathmere Capital Management LLC purchased a new stake in Oramed Pharmaceuticals during the 1st quarter valued at about $51,000. Hedge funds and other institutional investors own 12.73% of the company's stock.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc is a biopharmaceutical company focused on developing oral delivery technologies for biologic drugs, including proteins and peptides that are traditionally administered by injection. Its technology is designed to protect these therapies as they pass through the gastrointestinal tract and facilitate absorption into the bloodstream.

The company's lead programs have included ORMD-0801, an oral insulin candidate developed for the treatment of diabetes, and oral formulations of other peptide-based therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.